Whole-body edema with olanzapine: A case report and literature review.

Autor:	Cook EA; Clinical Pharmacist Specialist, The Robert J. Dole Veteran Affairs Medical Center, Wichita, Kansas; previously: The University of Texas at Tyler, Ben and Maytee Fisch College of Pharmacy, Tyler, Texas, elizabeth.cook1@va.gov., Shipman D; Clinical Pharmacist Specialist, The Robert J. Dole Veteran Affairs Medical Center, Wichita, Kansas; previously: The University of Texas at Tyler, Ben and Maytee Fisch College of Pharmacy, Tyler, Texas., Fowler TG; PGY-1 Pharmacy Resident, Christus Trinity Mother Frances Hospital, Tyler, Texas; previously: The University of Texas at Tyler, Ben and Maytee Fisch College of Pharmacy, Tyler, Texas.
Jazyk:	angličtina
Zdroj:	The mental health clinician [Ment Health Clin] 2020 Sep 30; Vol. 10 (5), pp. 291-295. Date of Electronic Publication: 2020 Sep 30 (Print Publication: 2020).
DOI:	10.9740/mhc.2020.09.291
Abstrakt:	Olanzapine is a second-generation antipsychotic (SGA) that has been shown to promote disease remission in persons with treatment-resistant depression when used in combination with fluoxetine. However, tolerability of treatment augmentation with SGAs may be limited because of common adverse effects, such as weight gain, hypertriglyceridemia, and elevated glucose. Data exist pertaining to rare localized edematous reactions or angioedema with use of SGAs, but diffuse whole-body edema has yet to be documented. A 47-year-old white female with treatment-resistant depression presented with a 5-day history of weight gain and swelling of her torso and extremities. Five days prior, she had initiated olanzapine/fluoxetine 6/50 mg daily following failure of fluoxetine 40 mg daily monotherapy. The patient was noted to have gained 3.6 kg since her last appointment and exhibited profuse pitting edema on her forearms, lower limbs, hands, and chest. Olanzapine/fluoxetine was discontinued and the patient was prescribed a 3-day course of a loop diuretic for symptomatic management. A follow-up visit 5 days later noted complete resolution of symptoms. Because of the temporal relationship of symptoms with initiation of olanzapine, we recommend monitoring for edema with initiation and/or titration of therapy. Competing Interests: Disclosures: The authors have no actual or potential conflicts of interest to disclose. (© 2020 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu